Patent ID: 8992912
Filing Date: 2015-03-31
Classification: A61K,A61P,C07K,G01N

Abstract:
1. A method for treating or inhibiting progression of cancer in a patient in need thereof, comprising administering an isolated antibody or an epitope-binding fragment or conjugate thereof that specifically binds to an EphA2 receptor to the patient, wherein the isolated antibody or epitope-binding fragment or conjugate thereof comprises a light chain variable region having at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NOS: 47, 48, 49, 50, and 52, and a heavy chain variable region having at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NOS: 32, 34, 36, 37, 38, 40, 42, 43, and 45, thereby treating or inhibiting progression of the cancer in the patient.